Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): A clinical trial

BMC Medicine

Volumn 7, Issue , 2009, Pages 60-

  Perroud, Nader ^a   Uher, Rudolf ^a   Marusic, Andrej ^b   Rietschel, Marcella ^c   Mors, Ole ^d   Henigsberg, Neven ^e   Hauser, Joanna ^f   Maier, Wolfgang ^g   Souery, Daniel ^h   Placentino, Anna ⁱ   Szczepankiewicz, Aleksandra ^f   Jorgensen, Lisbeth ^d   Strohmaier, Jana ^c   Zobel, Astrid ^g   Giovannini, Caterina ⁱ   Elkin, Amanda ^a   Gunasinghe, Cerisse ^a   Gray, Joanna ^a   Campbell, Desmond ^a   Gupta, Bhanu ^a   Farmer, Anne E ^a   McGuffin, Peter ^a   Aitchison, Katherine J ^a   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Laboratory for Virology   (Slovenia)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF ZAGREB   (Croatia)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g UNIVERSITY OF BONN   (Germany)

^h ERASME HOSPITAL   (Belgium)

ⁱ IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; OPEN STUDY; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SUICIDAL IDEATION; SUICIDE ATTEMPT;

EID: 70449726771     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-7-60     Document Type: Article

References (45)

1. World Health Organization Suicide prevention guidelines. , http://www.who.int/mental_health/prevention/suicide/suicideprevent/en/pr int.html
2. Henriksson S, Boethius G, Isacsson G. Suicides are seldom prescribed antidepressants: findings from a prospective prescription database in Jamtland county, Sweden, 1985-95. Acta Psychiatr Scand 2001, 103:301-306. 10.1034/j.1600-0447.2001.00276.x, 11328245.
3. Lonnqvist JK, Henriksson MM, Isometsa ET, Marttunen MJ, Heikkinen ME, Aro HM, Kuoppasalmi KI. Mental disorders and suicide prevention. Psychiatry Clin Neurosci 1995, 49(Suppl 1):S111-116. 10.1111/j.1440-1819.1995.tb01912.x, 9179954.
4. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005, 330:396. 10.1136/bmj.330.7488.396, 549110, 15718539.
5. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005, 330:385. 10.1136/bmj.330.7488.385, 549105, 15718537.
6. Suicide prevention in Europe. The WHO European monitoring survey on national suicide prevention programmes and strategies. , http://www.euro.who.int/document/E77922.pdf
7. Clinical review: relationship between antidepressant drugs and suicidality in adults. , http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf
8. Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2007, 164:1198-1205. 10.1176/appi.ajp.2007.07010007, 17671282.
9. Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D, McMahon FJ. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007, 164:1530-1538. 10.1176/appi.ajp.2007.06122018, 17898344.
10. Nelson JC, Delucchi K, Schneider L. Suicidal thinking and behavior during treatment with sertraline in late-life depression. Am J Geriatr Psychiatry 2007, 15:573-580. 10.1097/JGP.0b013e318050c9c2, 17586782.
11. Perlis RH, Beasley CM, Wines JD, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F, Strong RE, Rosenbaum JF. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 2007, 76:40-46. 10.1159/000096363, 17170562.
12. Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, Smoller JW. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007, 64:689-697. 10.1001/archpsyc.64.6.689, 17548750.
13. Szanto K, Mulsant BH, Houck PR, Dew MA, Dombrovski A, Pollock BG, Reynolds CF. Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age. J AffectDisord 2007, 98:153-161.
14. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004, 292:338-343. 10.1001/jama.292.3.338, 15265848.
15. Zisook S, Trivedi MH, Warden D, Lebowitz B, Thase ME, Stewart JW, Moutier C, Fava M, Wisniewski SR, Luther J. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STARD study. J Affect Disord 2009, 117:63-73. 10.1016/j.jad.2009.01.002, 19217668.
16. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000, 157:1445-1452. 10.1176/appi.ajp.157.9.1445, 10964861.
17. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005, 330:389. 10.1136/bmj.330.7488.389, 549107, 15718538.
18. Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K, Gardner D, Faulding J, Madeley R. Deliberate self-harm and antidepressant drugs. Investigation of a possible link. Br J Psychiatry 2000, 177:551-556. 10.1192/bjp.177.6.551, 11102331.
19. Embretson S, Reise S. Item response theory for psychologists. 2000, Mahwah, NJ, USA: Erlbaum.
20. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, Mors O, Elkin A, Williamson RJ, Schmael C. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008, 38:289-300. 10.1017/S0033291707001730, 17922940.
21. Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O, Henigsberg N, Souery D, Placentino A, Rietschel M. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 2009, 194:252-259. 10.1192/bjp.bp.108.057554, 19252156.
22. Grayson D, Bridges K, Cook D, Goldberg D. The validity of diagnostic systems for common mental disorders: a comparison between the ID-CATEGO and the DSM-III systems. Psychol Med 1990, 20:209-218. 10.1017/S0033291700013386, 2320696.
23. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states. Acta Psychiatr Scand 1975, 51:161-170. 10.1111/j.1600-0447.1975.tb00002.x, 1136841.
24. Ruhe HG, Dekker JJ, Peen J, Holman R, de Jonghe F. Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. Compr Psychiatry 2005, 46:417-427. 10.1016/j.comppsych.2005.03.001, 16275208.
25. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. 2005, College Station, TX, USA: Stata Press.
26. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies. , http://hydra.usc.edu/gxe
27. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006, 163:813-821. 10.1176/appi.ajp.163.5.813, 16648321.
28. Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006, 26:203-207. 10.1097/01.jcp.0000203198.11453.95, 16633153.
29. US Federal Drug Administration: Important Prescribing Information. , http://www.fda.gov/medWatch/SAFETY/2006/paroxetineDHCPMay06.pdf
30. Aursnes I, Tvete IF, Gaasemyr J, Natvig B. Suicide attempts in clinical trials with paroxetine randomised against placebo. BMC Med 2005, 3:14. 10.1186/1741-7015-3-14, 1198229, 16115311.
31. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006, 63:1358-1367. 10.1001/archpsyc.63.12.1358, 17146010.
32. Sharma A, Busnello JV, Ribeiro L, Thakur S, Whelan F, Elashoff RM, Wong ML, Licinio J. Suicidality scores during double-blind fluoxetine and desipramine treatment in Mexican Americans. J Clin Psychopharmacol 2007, 27:99-101. 10.1097/JCP.0b013e31802e2d76, 17224728.
33. Hall WD. How have the SSRI antidepressants affected suicide risk?. Lancet 2006, 367:1959-1962. 10.1016/S0140-6736(06)68860-0, 16782468.
34. Ohberg A, Vuori E, Klaukka T, Lonnqvist J. Antidepressants and suicide mortality. J Affect Disord 1998, 50:225-233. 10.1016/S0165-0327(98)00114-1, 9858081.
35. Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States, 1985-1999. J Clin Psychiatry 2004, 65:1456-1462.
36. Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 2001, 10:525-530. 10.1002/pds.618, 11828835.
37. Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants. BMJ 2005, 330:373-374. 10.1136/bmj.330.7488.373, 549094, 15718515.
38. Bondy B, Buettner A, Zill P. Genetics of suicide. Mol Psychiatry 2006, 11:336-351. 10.1038/sj.mp.4001803, 16462816.
39. Benazzi F. Mixed depression, suicidality, and antidepressants. J Clin Psychiatry 2006, 67:1650-1651.
40. Zisook S, Lesser I, Stewart JW, Wisniewski SR, Balasubramani GK, Fava M, Gilmer WS, Dresselhaus TR, Thase ME, Nierenberg AA. Effect of age at onset on the course of major depressive disorder. Am J Psychiatry 2007, 164:1539-1546. 10.1176/appi.ajp.2007.06101757, 17898345.
41. Beasley CM, Ball SG, Nilsson ME, Polzer J, Tauscher-Wisniewski S, Plewes J, Acharya N. Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials. J Clin Psychopharmacol 2007, 27:682-686. 10.1097/jcp.0b013e31815abf21, 18004137.
42. Balon R. Selective serotonin reuptake inhibitors and suicide: is the evidence, as with beauty, in the eye of the beholder?. Psychother Psychosom 2003, 72:293-299. 10.1159/000073025, 14526131.
43. Hirschfeld RM, Russell JM. Assessment and treatment of suicidal patients. N Engl J Med 1997, 337:910-915. 10.1056/NEJM199709253371307, 9302306.
44. Agerbo E, Gunnell D, Bonde JP, Mortensen PB, Nordentoft M. Suicide and occupation: the impact of socio-economic, demographic and psychiatric differences. Psychol Med 2007, 37:1131-1140. 10.1017/S0033291707000487, 17445281.
45. Brent DA, Mann JJ. Family genetic studies, suicide, and suicidal behavior. Am J Med Genet C Semin Med Genet 2005, 133C:13-24. 10.1002/ajmg.c.30042, 15648081.